Midazolam's Effects on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-lymphocytes

Int J Mol Sci. 2021 Jul 4;22(13):7198. doi: 10.3390/ijms22137198.

Abstract

Midazolam (MDZ) could affect lymphocyte immune functions. However, the influence of MDZ on cell's K+ currents has never been investigated. Thus, in the present study, the effects of MDZ on Jurkat T lymphocytes were studied using the patch-clamp technique. Results showed that MDZ suppressed the amplitude of delayed-rectifier K+ current (IK(DR)) in concentration-, time-, and state-dependent manners. The IC50 for MDZ-mediated reduction of IK(DR) density was 5.87 μM. Increasing MDZ concentration raised the rate of current-density inactivation and its inhibitory action on IK(DR) density was estimated with a dissociation constant of 5.14 μM. In addition, the inactivation curve of IK(DR) associated with MDZ was shifted to a hyperpolarized potential with no change on the slope factor. MDZ-induced inhibition of IK(DR) was not reversed by flumazenil. In addition, the activity of intermediate-conductance Ca2+-activated K+ (IKCa) channels was suppressed by MDZ. Furthermore, inhibition by MDZ on both IK(DR) and IKCa-channel activity appeared to be independent from GABAA receptors and affected immune-regulating cytokine expression in LPS/PMA-treated human T lymphocytes. In conclusion, MDZ suppressed current density of IK(DR) in concentration-, time-, and state-dependent manners in Jurkat T-lymphocytes and affected immune-regulating cytokine expression in LPS/PMA-treated human T lymphocytes.

Keywords: delayed-rectifier K+ current; inactivation kinetics; interleukin; intermediate-conductance Ca2+-activated K+ channel; lymphocyte; midazolam.

MeSH terms

  • Animals
  • Cytokines / metabolism
  • Delayed Rectifier Potassium Channels / antagonists & inhibitors*
  • Delayed Rectifier Potassium Channels / metabolism
  • Dose-Response Relationship, Drug
  • Flumazenil / pharmacology
  • GABA-A Receptor Antagonists / pharmacology
  • Humans
  • Hypnotics and Sedatives / administration & dosage
  • Hypnotics and Sedatives / pharmacology
  • Intermediate-Conductance Calcium-Activated Potassium Channels / antagonists & inhibitors*
  • Intermediate-Conductance Calcium-Activated Potassium Channels / metabolism
  • Jurkat Cells
  • Kinetics
  • Lipopolysaccharides / pharmacology
  • Lymphocyte Activation
  • Microscopy, Confocal
  • Midazolam / administration & dosage
  • Midazolam / pharmacology*
  • Patch-Clamp Techniques
  • Phytohemagglutinins / pharmacology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism*

Substances

  • Cytokines
  • Delayed Rectifier Potassium Channels
  • GABA-A Receptor Antagonists
  • Hypnotics and Sedatives
  • Intermediate-Conductance Calcium-Activated Potassium Channels
  • Lipopolysaccharides
  • Phytohemagglutinins
  • Flumazenil
  • Midazolam